Safety and Clinical Activity of TreandaTM (Bendamustine HCL) and Gemtuzumab Ozogamicin (GO, MylotargTM) in Combination Therapy for Patients Over Age 60 With Previously Untreated Acute Myeloid Leukemia.

Trial Profile

Safety and Clinical Activity of TreandaTM (Bendamustine HCL) and Gemtuzumab Ozogamicin (GO, MylotargTM) in Combination Therapy for Patients Over Age 60 With Previously Untreated Acute Myeloid Leukemia.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Dec 2012

At a glance

  • Drugs Bendamustine (Primary) ; Idarubicin (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Aug 2012 Planned End Date changed from 1 Aug 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top